Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing ...
Mikael Dolsten, the longtime Pfizer executive who led the companys research and development operations, has withdrawn his ...
The Wall Street Journal on MSN
Novo Nordisk Says Mikael Dolsten Won't Seek Election to Board at Friday's Meeting
Shareholders will vote Friday on the appointment of Lars Rebien Sorensen as chair, Cees de Jong as vice chair, and Britt Meelby Jensen and Stephan Engels as board members. Current board members Kasim ...
Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc.
Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity ...
Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary ...
The MarketWatch News Department was not involved in the creation of this content. NAPLES, Fla., Aug. 12, 2025 /PRNewswire/ -- MC Sciences, an emerging biotech developing first-in-class novel ...
NAPLES, Fla., Aug. 12, 2025 /PRNewswire/ -- MC Sciences, an emerging biotech developing first-in-class novel therapeutics backed by ROC Venture Group, proudly announces the appointment of Dr. Mikael ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback